Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers

This publication has 15 references indexed in Scilit:

• Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers
  Biochemical and Biophysical Research Communications, 1984
• Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation
  FEBS Letters, 1984
• OXIDATION POLYMORPHISM HAS CLINICAL RELEVANCE
  The Lancet, 1984
• Quinidine-induced rise in ajmaline plasma concentration
  Journal of Pharmacy and Pharmacology, 1984
• Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs
  Life Sciences, 1984
• Childhood leukaemia: a relationship between intracellular 6‐ mercaptopurine metabolites and neutropenia.
  British Journal of Clinical Pharmacology, 1983
• Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
  British Journal of Clinical Pharmacology, 1982
• Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man
  Life Sciences, 1980
• A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
  Journal of Medical Genetics, 1980
• POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
  The Lancet, 1977